On Wednesday, November 18, 2026, Vaccines and Biotechnology City (VBC) welcomed members of its Board of Directors, American investors from Kemin Industries, to review the City’s progress and see its capabilities firsthand.
During the visit, the Board members assessed how ready the human vaccine manufacturing facility, the veterinary vaccine manufacturing facility and VBC’s logistics infrastructure are. They expressed their satisfaction with the huge transformation the site has undergone.
The visit reflects international partners’ and investors’ continued confidence in VBC’s vision and its role in localizing vaccine manufacturing, in support of Egypt Vision 2030 and the African Union Agenda 2063.





